Healthcare IT NewsVineti closes on $33.5 million Series B financing to speed patient access to cell and gene therapiesHealthcare IT NewsCloud-based startup Vineti, co-founded by GE Ventures and Mayo Clinic Ventures, has closed on a $33.5 million Series… Continue reading
Healthcare IT NewsVineti closes on $33.5 million Series B financing to speed patient access to cell and gene therapiesHealthcare IT NewsCloud-based startup Vineti, co-founded by GE Ventures and Mayo Clinic Ventures, has closed on a $33.5 million Series… Continue reading
CRISPR RegulationGenomeWebCRISPR gene editing has opened up a number of opportunities to influence public health, eliminate pests, and treat human disease, but Amy Gutmann and Jonathan Moreno from the University of Pennsylvania write in an essay appear… Continue reading
KREM.comDr. Roger Dunteman on stem cell augmentation for roatator cuff repairKREM.comDr. Roger Dunteman on stem cell augmentation for roatator cuff repair. Studies are showing increased healing in rotator cuff surgeries with the help of stem cell augme… Continue reading
12news.com KPNX |
IMMUNOTHERAPY SHOWS PROMISE FOR LUNG CANCER
12news.com KPNX IMMUNOTHERAPY SHOWS PROMISE FOR LUNG CANCER. New research could change the way doctors treat patients with lung cancer. Immunotherapies have been shown to boost survival rates for the disease — which is the leading cause of cancer deaths. NBC’s Erika … |
Investor’s Business Daily |
GE’s Factory-In-A-Box Will Help It Expand This Key Business As Power Wilts
Investor’s Business Daily GE’s health care unit announced that the new KUBio “ready-to-run factory-in-a-box” can pump out viral vector-based vaccines, oncolytic viruses to treat cancer, and gene and cell therapies faster than a traditional, stick-built facility. If demand for a … GE Speeds Up Production of Viral Vector-Based TherapeuticsBioPharm International |
Investing News Network |
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
Investing News Network CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the presentation of new data from the company’s allogeneic chimeric antigen receptor T cell … |